60 years ago, the first randomised trial of adjuvant chemotherapy for breast cancer began.
1 Although the overall results were negative, the study did demonstrate a benefit in premenopausal women, especially those with nodal involvement. Henceforth began a race to eliminate clinically occult metastases and improve cure rates. This ambitious but worthy goal at times led to massive overtreatment, as was the case with myeloablative chemotherapy followed by autologous stem-cell rescue. Fortunately, major strides in molecular subtyping of breast cancer have substantially improved our ability to assess risk of disease recurrence, develop and use safer and more effective targeted therapies, and move towards an era of biologically rational treatment recommendations. Recent results from TAILORx represent a milestone achievement in reducing unnecessary exposure to cytotoxic chemotherapy in those who will be unlikely to derive benefit, 2 marking the entry into an era of de-escalation, where treatment is customised to a patient's risk to avoid overtreatment. So how are we to assimilate information from the meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) in The Lancet, 3 which seemingly contradicts this "less is more" approach, with its results demonstrating, rather convincingly, that increasing the dose intensity of adjuvant chemotherapy will benefit patients?
Two theories provide a rationale for dose intensification. The Goldie-Coldman hypothesis predicts that development of chemotherapy-resistant tumour clones could be prevented by use of dose-intense alternating drugs. 4 The Norton-Simon hypothesis, based on Gompertzian kinetics, predicts that smaller tumours grow more rapidly than larger tumours. 5, 6 As chemotherapy shrinks the tumour, an increase in growth between cycles occurs; thus, shorter intervals between each cycle should be more effective. These theories led to the development of multiple trials starting in the 1990s to test whether increasing the intensity of curative-intent chemotherapy by reducing the intervals between cycles, or by treating with drugs sequentially at full dose rather than concurrently at reduced doses, improves outcomes. Although some trials showed significant benefit with dose intensity, 7-9 others did not meet statistical significance, possibly because of underpowering. In the EBCTCG's meta-analysis 3 of trials comparing 2-weekly dose-dense versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy, the primary outcomes were recurrence and breast cancer mortality. With the inclusion of 37 298 patients treated in 26 trials and with a median follow-up of 7·4 years, the EBCTCG metaanalysis 3 showed a significant 3·4% absolute reduction (14% relative risk reduction) in breast cancer recurrences with dose intensification versus with standard-schedule chemotherapy (28·0% vs 31·4%, first-event rate ratio [RR] 0·86 [95% CI 0·82-0·89], p<0·0001). Additionally, the absolute 10-year breast cancer mortality was improved by 2·4% (18·9% vs 21·3%, RR 0·87 [95% CI 0·83-0·92], p<0·0001) and all-cause mortality was decreased by 2·7% (both with 13% relative risk reduction). Notably, patients included in this analysis had higher-risk disease as more than three-quarters had lymph-node-positive disease. Reassuringly, death without recurrence was similar when comparing the two treatment approaches.
Although these results are meaningful, several limitations should be recognised as we translate these findings into practice. First, the benefits of dose intensification have not been established in the era Dose intensification of chemotherapy for early breast cancer in the age of de-escalation of targeted therapy. Given that these studies enrolled women from 1985 to 2011, HER2 status was only known for 50% of tumours. Of those tested, 16% (n=2994) were HER2 positive. Use of trastuzumab was not reported but was probably uncommon since adjuvant trastuzumab was not approved until 2006. The remaining 18 625 patients did not have HER2 testing; thus, no HER2-directed therapy would have been given. Therefore, the majority of patients with HER2-positive breast cancer did not receive targeted therapy. Although the authors report that women with HER2-positive and HER2-negative disease benefit similarly from dose intensification, it is impossible to know whether dose intensification benefits trastuzumabtreated patients or those who receive more than one HER2-targeted therapy (pertuzumab, neratinib, or trastuzumab-emtansine). Similarly, if other targeted therapies such as CDK4/6 inhibitors and PARP inhibitors show significant benefit in the curative setting for highrisk oestrogen receptor (ER)-positive or BRCA-mutated breast cancer, prospective studies will be required to establish whether dose-intensive chemotherapy is better than standard chemotherapy in those settings.
Second, it is premature to conclude that patients older than 70 years or those with node-negative disease benefit from dose intensification, given the small number of patients in those groups and the fact that no significant benefit was observed for these patients. Moreover, gene-expression profiling was not used in these studies; thus, the benefit, if any, of a dose-intense approach for women with lymph-node-negative, highrisk, ER-positive disease is impossible to know. Finally, the use of dose intensification has not been studied in non-anthracycline, taxane-based regimens, which are being increasingly evaluated and used in women with node-negative, ER-positive disease. [10] [11] [12] [13] With these caveats in mind, the results of this metaanalysis are undoubtedly clinically important. In modern practice, if anthracycline-based chemotherapy is warranted, these data provide convincing evidence that a dose-intense approach should be considered. The data are strongest in node-positive disease but should be applied with caution in women with node-negative disease, in elderly patients, and in those with HER2-positive disease. As chemotherapy regimens continue to evolve and new targeted therapies enter the curative scene, prospective studies will be warranted to validate the dose-intense approach in these settings.
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